Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

REMARKS

Claims 1, 2, 5-7, 10-12, and 15-23 stand rejected. Claims 16-17 have been

objected to. Claims 16-17 have been amended.

Claim Objections

Claims 16-17 have been objected to for failing to include the objective

terminology which describes the trademarked product Tween 80. Claims 16-17

have been amended to correct this deficiency.

35 U.S.C. § 103(a) Rejections

Claims 1, 2, 5-7 and 10 stand rejected under 35 U.S.C. 103(a) for

purportedly being unpatentable over Komer U.S. Patent No. 5,773,422

("Komer") in view of Huet et al., U.S. Patent No. 6,482,425, ("Huet"). Applicant

respectfully disagrees and in view of the following remarks request that the

Examiner reconsider and withdraw the rejection.

Applicant respectfully submits that in order for a claim to be found

obvious, "the prior art reference (or references when combined) must teach or

suggest all the claim limitations." MPEP 706(j). The Office Action contends that

Komer discloses a pharmaceutical composition comprising ivermectin, propylene

glycol and poly sorbate 80 and benzyl alcohol but does not disclose the addition of

ethanol or isopropanol. The Office Actions further asserts that the Applicant has

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

03/00/2007

Attanna -- Di-t Na - 10101

Attorney Dkt. No.: 101918.56959C1

not shown "that N-methylpyrrolidone disclosed by Komer would materially affect

the basic and novel characteristic(s) of the claimed solution." Applicant

respectfully disagrees. The Applicant has discovered a novel aqueous

formulation of Ivermectin that is stable and palatable. Applicant's claimed

pharmaceutical solutions "consists essentially of" ivermectin, propylene glycol

and poly sorbate 80 and benzyl alcohol and do not require N-methylpyrrolidone

or 2-pyrrolidone. This limitation is not taught in Komer. In Komer, each and

every pharmaceutical solution disclosed includes either N-methylpyrrolidone or

2-pyrrolodone as necessary components to dissolve the invermectin. Komer

requires a pyrrolidone as a solubilizer. The solutions of the instant invention do

not require a pyrrolidone as a solubilizer. Clearly the used of a pyrrolidone, as

required by Komer, would "materially affect the basic and novel characteristic(s)

of the claimed solution." As such, Komer fails to teach or suggest the claimed

invention, which is limited to the claimed essential ingredients plus any

compounds present in impurity level concentrations. Huet does not compensate

for Komer's deficiencies.

The Examiner contends that Huet teaches that benzyl alcohol, ethanol

and isopropanol can interchangeably be used in invermectin containing

compositions. But Huet fails to teach a pharmaceutical composition limited to

the claimed essential ingredients and as such one of skill in the art would have

no motivation to remove N-methylpyrrolidone from Komer's compositions. As

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

stated above, in order for a claim to be found obvious the combined prior art

references must "teach or suggest all the claim limitations." MPEP 706(j). As

such, the combination of Komer and Huet fails to render the claimed invention

obvious.

Claims 10-12, 15 and 16 stand rejected under 35 U.S.C. 103(a) for

purportedly being unpatentable over Komer. Applicant respectfully disagrees

and in view of the following remarks requests that the Examiner reconsider and

withdraw the rejection of the claims.

Claim 10 depends on claim 6, which requires that the pharmaceutical

solution consists essentially of Ivermectin, 10-99% v/v isopropyl alcohol,

propylene glycol and polysorbate 80. As stated above, Komer only teaches

pharmaceutical solutions using N-methylpyrrolidone or 2-pyrrolodone as a

primary solvent to dissolve Ivermectin and as such fails to teach or suggest each

limitation of the claimed invention. Applicant's claimed pharmaceutical

solutions consist essentially of particular components and do not require N-

methylpyrrolidone or 2-pyrrolidone. In contrast, each and every pharmaceutical

solution disclosed by Komer also includes either N-methylpyrrolidone or 2-

pyrrolidone as necessary components to dissolve the invermectin. Furthermore,

Applicant's claimed pharmaceutical compositions comprise 10-99% isopropyl

alcohol, in addition to propylene glycol and polysorbate 80. Komer's Examples 14

and 17 and Col. 3, lines 6-45 do not disclose isopropyl alcohol. As such, Komer

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

fails to teach or suggest Applicant's claimed invention, which consists essentially

of ivermectin, 10-99% v/v isopropyl alcohol, propylene glycol and polysorbate 80

plus any compounds present in impurity level concentrations. Accordingly,

Applicant respectfully requests that the Examiner withdraw the rejection of

claims 10-12, 15 and 16 under 35 U.S.C. 103 based on Komer.

Regarding claims 11, 12, and 15, as discussed above, each and every

pharmaceutical solution disclosed by Komer also includes either N-

methylpyrrolidone or 2-pyrrolidone as necessary components to dissolve the

invermectin. Applicant's claimed pharmaceutical solution consists essentially of

particular components and does not require N-methylpyrrolidone or 2-

pyrrolidone. As such, Komer fails to teach or suggest the claimed invention and

Applicant respectfully requests that the Examiner reconsider and withdraw the

rejection of claims 11, 12 and 15 under 35 U.S.C. 103 in view of Komer.

Regarding the rejection of claim 16, as discussed above, each and every

formulation disclosed by Komer was prepared using either N-methylpyrrolidone

r 2-pyrrolidone as necessary components to dissolve the invermectin.

Applicant's method as claimed consists of particular steps that do not include

using either N-methylpyrrolidone or 2-pyrrolidone as necessary components to

dissolve the invermectin and Komer does not suggest excluding the step of

dissolving ivermectin in N-methylpyrrolidone or 2-pyrrolidone from the method.

As such Komer does not render Applicant's invention obvious and Applicant

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

101010 500500

Attorney Dkt. No.: 101918.56959C1

respectfully requests that the Examiner reconsider and withdraw the rejection of

claim 16 under 35 U.S.C. 103 in view of Komer.

Claims 17, 18, 22 and 23 stand rejected under 35 U.S.C. 103(a) for

purportedly being unpatentable over Komer in view of Lacy et al. U.S. Patent

No. 5,645,856 ("Lacy"). Applicant respectfully disagrees and in view of the

following remarks and amendments to the claims requests that the Examiner

reconsider and withdraw the rejection of the claims.

As discussed above, each and every pharmaceutical solution disclosed by

Komer was prepared using either N-methylpyrrolidone or 2-pyrrolidone as

necessary components to dissolve the invermectin. Applicant's methods as

claimed consist of particular steps that do not include using either N-

methylpyrrolidone or 2-pyrrolidone to dissolve the invermectin and Komer does

not suggest excluding N-methylpyrrolidone or 2-pyrrolidone from the method.

Lacy does not compensate for Komer's deficiencies. Lacy merely provides a list of

sweeteners (Col. 14, lines 2-3). As such Komer alone or in combination with Lacy

does not render Applicant's invention obvious. Applicant respectfully requests

that the Examiner reconsider and withdraw the rejection of claim 16 under 35

U.S.C. 103(a) over Komer in view of Lacv.

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

Claims 19-21 stand rejected under 35 U.S.C. 102(b) for purportedly being

anticipated by, or in the alternative, under 35 U.S.C. 103(a) for purportedly

being obvious over Komer.

The Examiner contends that if there are differences in amounts of the

components present in the Komer formulations and the claimed compositions,

such difference would appear minor in nature and the claimed compositions

would be prima facie obvious from Komer's disclosure. Applicant respectfully

disagrees.

The Examiner acknowledges that the claims are limited to the

terminology "consisting essentially of" but contends that Applicant failed to show

that N-methylpyrrolidone present in the formulation of Example 14 and 17

would materially affect the basic and novel characteristics of the claimed

invention (Office Action page 4). However, Komer's statements of the

unexpected solubility of avermectins in N-methylpyrrolidone and the advantages

of including N-methylpyrrolidone in his invermectin formulations (Col. 2, lines

47-61) demonstrate that one of skill in the art believes that N-methylpyrrolidone

materially affects the basic and novel characteristics of those formulations.

Therefore, one skilled in the art would also expect N-methylpyrrolidone to affect

the basic and novel characteristics of the claimed invention. As such, the term

"consisting essentially of" excludes N-methylpyrrolidone from the claimed

invention.

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

Komer does not teach or suggest pharmaceutical compositions consisting

essentially of ivermectin, propylene glycol and polysorbate 80 and therefore does

not anticipate or render the claimed invention obvious. In view of the foregoing

remarks, Applicant respectfully requests that the Examiner reconsider and

withdraw the rejection of claims 19-21 under 35 U.S.C. 102(b), or in the

alternative, under 35 U.S.C. 103(a) for purportedly being anticipated by, or

obvious over, Komer.

CONCLUSION

Applicant believes the present paper to be a complete and thorough

response to the Final Office Action. In view of the foregoing amendments and

remarks, the application is respectfully submitted to be in condition for

allowance. Accordingly, a timely favorable action is earnestly solicited.

If there are any questions regarding this amendment or the application in

general, a telephone call to the undersigned would be appreciated since this

should expedite the prosecution of the application for all concerned.

Amendment Dated: 09/06/2007

Reply to Office Action dated: 06/06/2007

Attorney Dkt. No.: 101918.56959C1

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #101918.56959C1).

Respectfully submitted,

September 6, 2007

John W. Ryan

Registration No. 33,771

Thomas M. Haas

Registration No. 50,210

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 Telephone No.: (202) 624-2500

Facsimile No.: (202) 628-8844